Patents by Inventor Eun Kyoung Yang

Eun Kyoung Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted piperidines having GPR119 agonistic activity
    Patent number: 10428055
    Abstract: The present invention relates to a substituted piperidines represented by following Chemical Formula 1, which have a GPR119 agonistic activity, a method for preparing the same, and a pharmaceutical composition including the same: wherein A, B, and X are defined therein.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: October 1, 2019
    Assignee: DONG-A ST CO., LTD.
    Inventors: Jae Sung Yang, Gye Rim Baek, Yoon Jung Kim, Chi Young Ahn, Jae Young Lee, Il Hoon Jung, Mi Kyung Kim, So Mi Kang, Hyo Ju Lee, Yu Na Chae, Ye Hwang Cheong, Tae Hyoung Kim, Eun Kyoung Yang, Moon Ho Son, Chang Yell Shin
  • COMPOUND HAVING GPR119 AGONISTIC ACTIVITY, METHOD FOR PREPARING THE SAME, AND PHARMAECUTICAL COMPOSITION INCLUDING THE SAME AS EFFECTIVE COMPONENT
    Publication number: 20190092763
    Abstract: The present invention relates to a novel compound having a GPR119 agonistic activity, a method for preparing the same, and a pharmaceutical composition including the same as an effective component. The present invention has an effective hypoglycemic action and an effect on pancreatic beta cells, and also improves lipid metabolism which is a chronic cardiovascular risk factor, thereby having a treatment and/or prevention effect of a metabolic disease such as diabetes.
    Type: Application
    Filed: July 24, 2015
    Publication date: March 28, 2019
    Applicant: DONG-A ST CO., LTD.
    Inventors: Jae Sung Yang, Gye Rim Baek, Yoon Jung Kim, Chi Young Ahn, Jae Young Lee, Il Hoon Jung, Mi Kyung Kim, So Mi Kang, Hyo Ju Lee, Yu Na Chae, Ye Hwang Cheong, Tae Hyoung Kim, Eun Kyoung Yang, Moon Ho Son, Chang Yell Shin
  • Pharmaceutical composition for prevention and treatment of diabetes or obesity comprising a compound that inhibits activity of dipeptidyl peptidase-IV, and other antidiabetic or antiobesity agents as active ingredients
    Patent number: 8440669
    Abstract: The present invention relates to a pharmaceutical composition for the prevention and treatment of diabetes or obesity comprising as active ingredients a compound which inhibits the activity of dipeptidyl peptidase-IV (DPP-IV), a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, and one or more other antidiabetic or antiobesity agents. The pharmaceutical composition exhibits excellent glucose tolerance and may be useful in the prevention and treatment of diabetes, obesity, and the like by effectively inhibiting blood glucose levels and reducing fat mass.
    Type: Grant
    Filed: October 16, 2009
    Date of Patent: May 14, 2013
    Assignee: Dong-A Pharmaceutical Co. Ltd.
    Inventors: Chang Yell Shin, Song-Hyen Choi, Yu Na Chae, Eun Kyoung Yang, Gook Jun Ahn, Moon-Ho Son, Heung Jae Kim, Woo Young Kwak, Jong Pil Min, Tae Hyun Yoon, Soon Hoe Kim, Moohi Yoo
  • PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE AND THE METHOD FOR PREVENTION OR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE USING THE SAME
    Publication number: 20130072459
    Abstract: The present invention provides a pharmaceutical composition for the prevention and treatment of a non-alcoholic fatty liver disease (NAFLD), containing an active ingredient selected from the group consisting of Compound 1 represented by formula 1, sitagliptin, vildagliptin, linagliptin or a pharmaceutically acceptable salt thereof. Further, the present invention provides a method for the prevention or treatment of a non-alcoholic fatty liver disease, including administering an effective amount of an active ingredient selected from the group consisting of Compound 1 represented by formula 1, sitagliptin, vildagliptin, linagliptin or a pharmaceutically acceptable salt thereof to a mammal including a human in need thereof. Further, the present invention provides use of Compound 1 represented by formula 1, sitagliptin, vildagliptin, linagliptin or a pharmaceutically acceptable salt thereof, for manufacturing a pharmaceutical composition for the prevention or treatment of a non-alcoholic fatty liver disease.
    Type: Application
    Filed: March 23, 2011
    Publication date: March 21, 2013
    Inventors: Gook-Jun An, Eun-Kyoung Yang, Eun-Jung Cho, Yu-Na Chae, Song-Hyen Choi, Ha-Dong Kim, Chang-Yell Shin, Mi-Kyung Kim, Woo-Young Kwak, Heung-Jae Kim, Moon-Ho Son, Soon-Hoe Kim
  • Pharmaceutical Composition for Prevention and Treatment of Diabetes or Obesity Comprising a Compound that Inhibits Activity of Dipeptidyl Peptidase-IV, and other Antidiabetic or Antiobesity Agents as Active Ingredients
    Publication number: 20110201624
    Abstract: The present invention relates to a pharmaceutical composition for the prevention and treatment of diabetes or obesity comprising as active ingredients a compound which inhibits the activity of dipeptidyl peptidase-IV (DPP-IV), a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, and one or more other antidiabetic or antiobesity agents. The pharmaceutical composition exhibits excellent glucose tolerance and may be useful in the prevention and treatment of diabetes, obesity, and the like by effectively inhibiting blood glucose levels and reducing fat mass.
    Type: Application
    Filed: October 16, 2009
    Publication date: August 18, 2011
    Applicant: DONG-A PHARMACEUTICAL. CO., LTD
    Inventors: Chang Yell Shin, Song-Hyen Choi, Yu Na Chae, Eun Kyoung Yang, Gook Jun Ahn, Moon-Ho Son, Heung Jae Kim, Woo Young Kwak, Jong Pil Min, Tae Hyun Yoon, Soon Hoe Kim, Moohi Yoo